News
April 2010
Domainex and scientists led by Professor Alan Ashworth of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research have discovered drug-like compounds that inhibit an enzyme from the PARP superfamily. Domainex will now provide lead optimisation services that will assist Ashworth's team to develop drug candidates targeting this enzyme. The programme recently received a £4 million research grant under the Wellcome Trust's Seeding Drug Discovery Initiative. More...
Domainex has secured further financing to develop its Combinatorial Domain Hunting (CDH) technology, and to advance its internal pipeline of oncology targets. The two-stage funding round will bring in a significant investment from Longbow, The Capital Fund, Bury Fitzwilliam-Lay & Partners LLP, and Takeda Research Investment, Inc. (TRI). The involvement of TRI represents an important recognition of the value of Domainex’s unique CDH technology, and of its novel oncology pipeline. More...
Domainex makes a breakthrough on novel protein-protein interaction cancer target: our scientists have been instrumental in identifying small-molecule inhibitors of the Neuropilin 1 – VEGF-A interaction, thereby demonstrating that this is an important target for the development of novel anticancer therapeutics. The work, reported in the latest edition of the Journal of Medicinal Chemistry, was carried out by Domainex on behalf of its client Ark Therapeutics. Protein-protein interactions have for a long time been considered tough targets for small-molecule drug discovery, but Domainex has demonstrated that its approach, based on high-quality structure based drug design and insightful medicinal chemistry, is able to crack even difficult problems such as these.
Domainex and Pharmidex announce a strategic drug discovery services alliance. More
January 2010:
Professor Salvador Moncada, a director of Domainex, received a knighthood for services to Science in the 2010 New Year's Honours List. Professor Moncada is Director of the Wolfson Institute of Biomedical Research at UCL, and he has made ground-breaking discoveries in cardiovascular pharmacology of major significance to translational medicine over a period of more than three decades.
Dr Trevor Perrior, Director of Research for Domainex has been appointed Visiting Professor of Medicinal Chemistry at the University of Sussex.
Domainex Ltd has released the next generation of its LeadBuilder virtual screening technology. LeadBuilder has been designed to be ideally suited to the needs of university groups engaged in Translational Research, and to emerging biotechnology and pharmaceutical companies. More
Domainex announced a collaboration on exciting drug discovery programmes with the Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.
Domainex will be sponsoring and presenting at PEGS - The Protein Expression Summit, which will be held in Boston MA, 6-10 April 2009. More
Domainex launches its new corporate identity and website.
May 2008:
Professor Laurence Pearl, founder and CSO of Domainex, elected a Fellow of the Royal Society.
May 2007:
Dr Eddy Litter joins Domainex as Chief Executive Officer; Dr Keith Powell becomes Chairman.
May 2007:
Domainex merges with NCE Discovery.
October 2005:
Domainex CSO, Professor Laurence Pearl, elected to EMBO.
July 2005:
Dr Renos Savva wins prestigious London Young Biotechnology Entrepreneur of the Year Award.
News item heading
Eriuscip enibh etum quatuerit adio commy nullametum volum irit adigna alis am, commy nit ad modit accum ad et, sequatet venibh ero euipsum eu facin exer autem vullaore elesendio ex ero duis dolorperat, vel euisit lam velisci te magnit, quisit ulluptate feuguer aessim ing et, sum dolore ming eugait alisci tetue dolor sit ullam zzril eui et la feugiat.
News item heading
Eriuscip enibh etum quatuerit adio commy nullametum volum irit adigna alis am, commy nit ad modit accum ad et, sequatet venibh ero euipsum eu facin exer autem vullaore elesendio ex ero duis dolorperat, vel euisit lam velisci te magnit, quisit ulluptate feuguer aessim ing et, sum dolore ming eugait alisci tetue dolor sit ullam zzril eui et la feugiat.
